CDP870 studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Preliminary data from a Phase III trial examining the pegylated TNF inhibitor in combination with methotrexate in patients with moderate to severe rheumatoid arthritis is positive, Celltech reports. A significant response in the primary endpoint, ACR20, was seen at week one and maintained for the study's six-month duration. A Phase III monotherapy trial is slated to conclude in the third quarter. Celltech plans to commence the remainder of the Phase III program in the second half of 2004. Pfizer had decided to delay initiation of further Phase III studies until results from the RA studies were seen. Phase III trials in Crohn's disease are ongoing, with submission planned for 2005...